Emerald Health Therapeutics Inc. (TSX-Venture:EMH) stood out midday Thursday from the usual gloom of downward markets, with exciting news about its product.
The Toronto-based company recently announced it has filed 17 provisional U.S. patent applications covering Emerald's unique Defined Dose cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald's intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.
The products provide more precise and consistent delivery, dosage, and formulations. Defined Dose cannabis products will, when made available to the public, provide consumers with products currently not available.
According to Emerald CEO Chris Wagner, "We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety enhanced through GMP-compliant production and enhanced product utility achieved through knowledge of science. Emerald's filing of these patent applications is an important step.”
Share prices grew 13 cents, or 3.3%, to $4.10, on heavy volume of 339,000 shares.
